Nextgen rbis ORA health fraud surveillance platform development, modernization and enhancement (DME) & operations and maintenance (o & m)
Ended Awarded Last action
- Contract number
- 75F40123F19005
- Awardee
-
Booz Allen Hamilton Inc. UEI JCBMLGPE6Z71 Part of Booz Allen Hamilton Holding Corporation
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $669,034
Award facts
- Contract value 100% obligated
- $669,034.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541511 Custom Computer Programming Services
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Labor Hours
- Place of performance
- Calverton, MD 20705, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$1,284 | |
| Other Administrative Action | $0 | |
| Original award | $670,318 |
About this award
Booz Allen Hamilton Inc. received a contract award from the Food and Drug Administration (FDA) for the NextGen RBIS ORA Health Fraud Surveillance Platform Development, Modernization and Enhancement (DME) and Operations and Maintenance (O&M). This contract, issued as a Blanket Purchase Agreement (BPA) call under the General Services Administration's Multiple Award Schedule (MAS), carries a ceiling value of $669,034.16 and operates on a labor-hours pricing model. The award is a modification to update accounting information for the existing platform development and maintenance effort. The contract was awarded on March 24, 2023, with an ultimate completion date of March 24, 2024, and will be performed in Calverton, Maryland.
The NextGen RBIS ORA platform supports the FDA's Office of Regulatory Affairs' critical health fraud surveillance capabilities, combining development, modernization, and enhancement activities with ongoing operations and maintenance services. Booz Allen Hamilton, a McLean, Virginia-based management, technology, and engineering services firm with extensive experience supporting federal civilian agencies, is well-positioned to deliver these services given its substantial portfolio of FDA task orders spanning electronic submissions, regulatory science optimization, and biomarker tracking support. This award does not carry a small business set-aside designation, reflecting Booz Allen Hamilton's status as a large business prime contractor competing in full and open competition.
Quick answers
Who was awarded contract 75F40123F19005?
75F40123F19005 was awarded to Booz Allen Hamilton Inc. by Food and Drug Administration (Department of Health and Human Services) on March 24, 2023.
How much is contract 75F40123F19005 worth?
The government has obligated $669,034 on 75F40123F19005.
Is contract 75F40123F19005 an order under another contract?
Yes. 75F40123F19005 is a BPA call under GS35F386DA-75F40122A00013, a blanket purchase agreement, on Multiple Award Schedule (MAS).
Was contract 75F40123F19005 competed?
The extent of competition for 75F40123F19005 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award